Ribociclib,goserelin acetate
Novartis
['mbc']
 that was evaluated in the amalee trial for mbc. amalee did not demonstrate noninferiority of the 400- vs 600-mg dose of rib using orr as the primary endpoint.
Medical oncologist. National Cancer Institute, Mexico City